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Abstract 
Purpose: To investigate the anti-osteoporosis effect of Astragalus membranaceus (Fisch.) Bunge. 
extract (AMBE) in experimental rats.  
Method: Female Sprague-Dawley rats were randomly divided into six groups: control group, 
ovariectomy (OVX) with vehicle group, OVX with 17β-estradiol (E2, 25 µg/kg/day) group, and OVX with 
AMBE doses (60, 120 and 240 mg/kg/day) groups. Daily oral administration of AMBE or E2 was started 
4 weeks after OVX and lasted for 16 weeks. The bone mineral density (BMD) of L4 vertebrae and right 
femurs was evaluated. The length of each femur was measured with a micrometer, and the center of 
diaphysis was determined. Three representative L4 vertebrae were selected to evaluate trabecular 
microarchitecture. Serum alkaline phosphatase (ALP), urinary calcium (U-Ca), urinary phosphorus (U-
P), urinary creatinine (Cr) and osteocalcin (OC) levels were measured.  
Results: AMBE dose-dependently inhibited the bone mineral density (BMD) reduction of L4 vertebrae 
(0.27 ± 0.03 g/cm2, p < 0.05) and femurs (0.23 ± 0.03 g/cm2, p < 0.05) caused by OVX and prevented 
the deterioration of trabecular microarchitecture (p < 0.05), which were accompanied by a significant 
decrease in skeletal remodeling (p < 0.05) as evidenced by the lower levels of bone turnover markers. A 
higher dosage of AMBE treatment (240 mg/kg/day) increased U-Ca/Cr (0.27 ± 0.03 mmol/mmol), ALP 
(137.23 ± 16.72 U/L), U-P/Cr (4.18 ± 0.27 mmol/mmol) and OC (8.47 ± 0.26 mmol/L) levels (both p < 
0.05). 
Conclusion: The findings of this study indicate that AMBE prevents OVX-induced osteoporosis in rats.  
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Osteoporosis is a common systemic skeletal 
condition among older people. Currently, 2.2 
million people have osteoporosis and for those 
aged 50 and over, up to one in four men and two 
in five women will experience a minimal trauma 
fracture [1,2]. Osteoporosis is a generalised 
skeletal disorder characterised by decreased 
bone mass and deteriorated bone architecture. 
Osteoporosis results in an increased 
susceptibility to bone fractures, and accelerated 
bone loss is correlated with an increased post-
fracture mortality risk; thus, osteoporosis is a 
major health concern [3]. In the elderly, hip 
fractures are closely associated with mortality [4]. 
Hormone deficiency is known to impair 
cancellous metaphyseal bone and reduce BMD 
in humans and animals. Therefore, estrogen 
deficiency in post-menopausal women has been 
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regarded as a critical cause of this population’s 
susceptibility to osteoporosis [5]. Osteoporosis is 
twice as common in women as in men [6-8]. 
 
Among recent drugs, adjuvant hormone 
antagonist therapies aromatase inhibitors in 
women who have undergone surgery for breast 
cancer, gonadotropin releasing hormone (GnRH) 
agonists in men with prostate cancer] need 
special attention. Treatment with these drugs 
results in a progressive decrease in BMD, 
although a role for independent factors for 
fracture risk cannot be excluded [9-13]. Other 
medicines that stimulate bone formation (e.g., 
growth hormone, sodium fluoride, and 
parathyroid hormone) or inhibit bone resorption 
(e.g., bisphosphonates and calcitonin) may 
prevent bone loss progression in established 
osteoporosis. However, these medications are 
not suitable for a large proportion of the world 
population, especially in developing countries, 
and these drugs have side effects, such as 
gastrointestinal reactions, cancers, osteonecrosis 
of the jaw, and reduced skeletal strength [14,15]. 
Consequently, there is a need to develop new 
drugs with improved therapeutic efficacy and 
fewer undesirable side effects. 
 
Astragalus membranaceus (Fisch.) Bunge. has 
been widely used as an anti-osteoporosis herb in 
traditional medicine for many years in China [16-
19]. This study was designed to investigate the 




Collection and preparation of Astragalus 
membranaceus extract 
 
The herbal samples of Astragalus 
membranaceus (Fisch.) Bunge. were collected 
from Shiyan City, Hubei Province in China in May 
2015. Taxonomic identification of the plant was 
performed by Professor ZhiHu of Changchun 
University of Chinese Medicine, in China. A 
voucher specimen (no. AMBE 201505016) was 
deposited in College of Pharmacy, Changchun 
University of Chinese Medicine, China for future 
reference. 
 
One batch of herbal samples Astragalus 
membranaceus (Fisch.) was dried in an oven. 
AMBE was obtained by steeping the dried 
Astragalus membranaceus (Fisch.) in water at 60 
oC three times for one hour each. Then the 
extracted fluid was dried in an oven and freeze-
dried to obtain the last extract. One gram powder 
was equivalent to about 1.8 g crude samples. 
The yield was 55.67 %. 
Animals and treatments 
 
Female Wistar rats (weighing 200 ± 20 g) were 
provided by the Experimental Animal Center of 
Jilin Province (Certificate no. SYXK2003-0006). 
The animals had free access to feed and water, 
and were allowed to acclimatize for at least one 
week before use. The rat experiment was 
approved by the Animal Care and Use 
Committee of Changchun University of Chinese 
Medicine (approval ref no. 20100308) and was 
carried out in compliance with Directive 
2010/63/EU on the handling of animals used for 
scientific purposes [20]. 
 
Sixty rats were randomly divided into six groups 
of ten rats each: control group, ovariectomy 
(OVX) with vehicle group, OVX with 17ß-
estradiol (E2, 0.025 mg/kg/day) group, and OVX 





The BMD of L4 vertebrae and right femurs of rats 
was measured using dual-energy x-ray 
absorptiometry scanning. The measurement was 
expressed as gram of mineral contents per cm2 
of surface area.  
 
Three-point bending test 
 
After the animals were sacrificed by cervical 
dislocation, they were used for three-point 
bending test. The left femurs of rats were slowly 
thawed at room temperature. The length of each 
femur (distance from the intermalleolar to the 
intercondylar region) was measured with a 
micrometer, and the center of the diaphysis was 
determined. 
 
Serum and urine specimen analysis 
 
Serum alkaline phosphatase (ALP), urinary 
calcium (U-Ca), urinary phosphorus (U-P), and 
urinary creatinine (Cr) levels were measured on 
an automatic analyzer using a diagnostic reagent 
kit. Serum osteocalcin (OC) concentration was 




The data are expressed as mean ± standard 
deviation (SD). Statistical analysis was 
performed using one-way ANOVA combined with 
Bonferroni’s multiple comparison test using 
SPSS 18.0. Differences were considered 
statistically significant at p < 0.05. 
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BMD of L4 vertebrae and femur 
 
BMD results for rat L4 vertebrae and femur are 
shown in Table 1. Compared with control group, 
OVX significantly decreased the BMD in the L4 
vertebrae and femurs (both p < 0.05). However, 
AMBE treatment prevented the BMD decrease in 
OVX-induced L4 vertebrae and femurs (all p < 
0.05) in a dose-dependent manner compared to 
the OVX group. E2 also significantly increased 
the BMD of the L4 vertebrae and femurs (both p 
< 0.05). 
 
Mechanical properties of femur 
 
The femur mechanical testing result sees Table 
2. Compared with the sham group, 16 weeks of 
estrogen deficiency significantly decreased the 
maximum load and maximum stress (both p < 
0.05). Higher dosage of AMBE treatments (120 
or 240 mg/kg/day) markedly prevented the OVX-
induced tendency to decrease these parameters 
(both p < 0.05). E2 also increased the above-
mentioned biomechanical parameters, which 
were significantly higher than those of the OVX 
group (all p < 0.05). 
 
Biochemical profile of rat serum and urine  
 
The effects of AMBE on biochemical parameters 
in the serum and urine of OVX rats sees Table 3. 
Compared with the sham group, the levels of U-
Ca/Cr, U-P/Cr, ALP, and OC were significantly 
increased in the OVX group (all p < 0.05). All 
three AMBE doses increased U-Ca/Cr and ALP 
levels (all p < 0.05) in a dose-dependent manner. 
Higher dosage of AMBE treatment (120 or 240 
mg/kg/day) increased U-P/Cr and OC levels 
(both p < 0.05). Again, E2 administration also 
reversed the above-mentioned increases, which 
were statistically significant. 
 
 
       Table 1: Effect of AMBE on BMD of L4 vertebrae and femur (n = 10) 
 
Group Dosage (mg/kg) 
BMD of vertebrae 
(g/cm2) 
BMD of femurs 
(g/cm2) 
Control - 0.29±0.02* 0.26±0.02* 
OVX - 0.18±0.03 0.12±0.03 
E2 0.025 0.24±0.04* 0.21±0.02* 
L-AMBE 60 0.20±0.03* 0.15±0.03* 
M-AMBE 120 0.25±0.03* 0.19±0.04* 
H-AMBE 240 0.27±0.03* 0.23±0.03* 
* p < 0.05 and ** p < 0.01 versus OVX group. L-AMBE: low dose of AMBE, M-AMBE: middle dose of 
AMBE, H-AMBE: high dose of AMBE 
 
Table 2: Effect of AMBE on femur mechanical properties (n = 10) 
 





Control - 118.3±4.9* 216.7±5.4* 
OVX - 88.7±5.2 137.1±6.2 
E2 0.025 121.5±4.7* 194.3±5.6* 
L-AMBE 60 92.3±5.4 162.5±6.8 
M-AMBE 120 98.6±4.1* 182.2±5.6* 
H-AMBE 240 116.1±4.5* 197.4±5.1* 
* P < 0.05 and ** p < 0.01 versus OVX group. L-AMBE: low dose of AMBE, M-AMBE: middle dose of 
AMBE, H-AMBE: high dose of AMBE 
 
Table 3: Effect of AMBE on biochemical of rat serum and urine (n = 10) 
 









control - 0.19±0.03* 3.27±0.31* 103.72±11.35* 6.71±0.31* 
OVX - 0.47±0.02 5.48±0.28 201.54±26.43 14.26±0.43 
E2 0.025 0.23±0.03* 4.33±0.25* 132.27±16.46* 8.54±0.27* 
L-AMBE 60 0.41±0.03* 5.53±0.45 176.32±17.21* 12.35±0.32 
M-AMBE 120 0.36±0.02* 4.62±0.39* 148.26±15.76* 11.64±0.28* 
H-AMBE 240 0.27±0.03* 4.18±0.27* 137.23±16.72* 8.47±0.26* 
* p < 0.05 and ** p < 0.01 versus OVX group. L-AMBE: low dose of AMBE, M-AMBE: middle dose of AMBE, H-
AMBE: high dose of AMBE 
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Osteoporosis poses a significant public health 
issue. The use of drugs registered for the 
treatment of osteoporosis are recommended 
when the benefits overcome the risk. Despite the 
pharmacological and clinical advantages of HRT 
as a widely accepted therapeutic strategy for 
osteoporosis, serious side effects of long-term 
application have also been reported. Therefore, 
new therapeutic drugs for osteoporosis is 
urgently needed. In recent decades, Chinese 
medicine have been extensively investigated for 
their pharmacological effects related to bone 
protection. The present study is the first to 
demonstrate the beneficial effects of AMBE 
against OVX-induced osteoporosis in rats. In our 
study, high dose of AMBE significantly improved 
the bone mass, bone strength, bone 
microarchitecture, and bone turn-over in OVX-
induced osteoporotic rats. These results revealed 
AMBE could be used as a natural alternative for 
treating osteoporosis. 
 
Bone remodeling is the natural process that 
mediates changes in the traits that influence 
bone strength. Any interruption in bone 
remodeling, such as menopause, will disturb the 
balance between formation and resorption and 
cause bone mass loss [21,22]. We used OVX 
rats as an animal model for human osteoporosis 
in vivo experiments. It has been reported that 
statistically significant bone loss can be seen 
after 30 days of treatment [23]. Consistent with 
other studies, OVX caused significantly higher 
body weights in our present study, which may be 
attributed to fat deposition caused by the lack of 
estrogen [24]. Previous studies suggest that 
estrogen plays an important role in stimulating 
the differentiation of progenitor cells through the 
osteoblast lineage but not the adipocyte lineage 
[25]. 
 
The amount of bone present in the body, bone 
mineral content, and bone mineral density are 
parameters measured to determine whether a 
person is osteoporotic. Bone strength is 
dependent on both the quantity of minerals 
present (BMD) and the quality of the bone. Bone 
re-modelling is a major determinant of bone 
strength. Bone quality is a function of bone 
morphology and architecture as well as of bone 
material properties. Decreased BMD is one of 
the major factors jeopardizing bone strength, 
resulting in increased susceptibility to fractures 
[26]. Thus, BMD measurement can best predict 
fracture risk [27]. This study showed that OVX 
reduced BMD in the right femurs and L4 
vertebrae, which are rich in trabecular bone, 
while treatment with AMBE dose-dependently 
prevented the decreases in BMD. Although BMD 
is among the strongest predictors of facture 
resistance, both empirical observations and 
theoretical analyses show that the biomechanical 
properties of bone and trabecular 
microarchitecture trabecular bone strength as 
well [28]. The present study revealed that higher 
doses of AMBE prevented the OVX-induced 
tendency toward decreased biomechanical 
parameters. 
 
Furthermore, bone marker measurement plays a 
role in osteoporosis diagnosis and treatment [29]. 
Enhanced ALP, OC, U-Ca/Cr, and U-P/Cr levels 
indicated upregulation of bone turnover by OVX. 
The bone turnover markers above were dose-
dependently reversed by AMBE, indicating a 





The findings of this study indicate that AMBE is 
effective in the treatment of osteoporosis in rats. 
Thus, AMBE has a potential to be developed as 
a natural alternative treatment agent to treat 
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